Microbiota in Coronary Artery Disease
Microbiota and Clinical Disorders: Neuroimmunology to Cardio-Pulmonary Links, NOVA Publications , ss.183-197, 2026
- Yayın Türü: Kitapta Bölüm / Araştırma Kitabı
- Basım Tarihi: 2026
- Yayınevi: NOVA Publications
- Sayfa Sayıları: ss.183-197
- Anahtar Kelimeler: coronary artery disease (CAD), diet, dysbiosis, gut microbiota, inflammatory mediators
- Atatürk Üniversitesi Adresli: Evet
Özet
Coronary artery disease (CAD) remains one of the most prevalent causes of global morbidity and mortality, predominantly driven by atherosclerotic processes that are exacerbated by modifiable risk factors including hypertension, diabetes mellitus, obesity, tobacco use, and unhealthy lifestyle behaviors. Despite advances in early diagnosis and treatment, CAD remains a significant health issue, particularly in individuals over the age of 35. Emerging evidence indicates a potential association between gut microbiota dysbiosis and the pathogenesis of coronary artery disease. The composition and function of the gut microbiota—modulated by genetic predisposition, age, dietary patterns, and environmental influences—appear to play a pivotal role in modulating systemic inflammation and atherogenic processes. Microbial metabolites and toxins, such as trimethylamine-N-oxide (TMAO), endotoxins such as lipopolysaccharide (LPS), and short-chain fatty acids (SCFAs), have been identified as significant contributors to arterial inflammation and the progression of CAD. Dietary factors, such as the consumption of red meat, eggs, and dairy products, can increase CAD risk by promoting TMAO production, while fiber-rich diets like the Mediterranean diet may reduce this risk. Probiotics and prebiotics hold promise in improving CAD outcomes by regulating inflammation and promoting beneficial gut bacteria. However, further clinical studies are needed to explore the therapeutic potential of microbiota-targeted interventions. This review highlights the critical role of gut microbiota in the pathogenesis of CAD and emphasizes the potential of dietary and microbial interventions in reducing CAD risk. Fecal microbiota transplantation emerges as a promising novel therapeutic approach to prevent CAD development.